Compare Natera Inc. Common Stock (NTRA) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Rigetti Computing Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Rigetti Computing Inc trades at $11.53 (market cap $4.27B). The key difference: Natera Inc. Common Stock is far larger — about 13.4× Rigetti Computing Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Rigetti Computing Inc for 36 Days on average.
| NTRA | RGTI | |
|---|---|---|
Market Cap | $57.03B | $4.27B |
Volume | 1,131,157 | 14,966,259 |
Sector | Health | Technology |
52-Week High | $425.64 | $56.34 |
52-Week Low | $179.42 | $11.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $56.18B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RGTI trades at $12.78, down 3.55% today, with bearish technical signals but strong analyst support. The company shows negative profitability with a -1,787.4% net income margin despite recent earnings beats. Revenue growth from $7M to $13M (2025-2026) is overshadowed by escalating losses. Cash flow remains negative, though financing activities provide liquidity. Recent quantum computing sector news highlights competitive positioning and technological advancements.
Outlook remains speculative with high execution risk; Wall Street consensus is bullish (85.7% buy ratings) with a $21.67 price target implying 70% upside. Key risks include sustained losses, intense competition, and reliance on future quantum technology adoption. The stock offers high-risk growth potential for investors comfortable with speculative emerging technology plays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
